Leqvio International Purchase Legalities: What U.S. Patients Need to Know in 2026

What Leqvio Is and Why Cost Is a Barrier

Leqvio is a small interfering RNA (siRNA) therapy that silences hepatic PCSK9 synthesis, lowering LDL cholesterol by roughly 50% with only two injections per year after the loading schedule. The FDA approved it on December 22, 2021, for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease requiring additional LDL lowering. [1]

The twice-yearly dosing is convenient, but the wholesale acquisition cost runs approximately $3,500 to $4,000 per injection in the United States, putting annual drug spend near $7,000 to $8,000 before any rebates or discounts. [2] That gap between list price and what a patient actually pays drives many people to ask whether purchasing inclisiran from Canada, the United Kingdom, or other markets is legal and practical.

Clinical Efficacy That Justifies the Cost Conversation

The ORION-10 trial (N=1,561) demonstrated a 52.3% placebo-adjusted reduction in LDL-C at day 510 with inclisiran 284 mg every six months (P<0.0001). [3] ORION-9 (N=482), focused on heterozygous familial hypercholesterolemia, showed a 39.7% placebo-adjusted LDL-C reduction at day 510. [4] The 2022 ACC/AHA guideline on nonstatin therapies states that PCSK9 inhibitors and PCSK9 siRNA agents are reasonable additions when LDL-C remains above goal on maximally tolerated statin therapy. [5]

These efficacy data support the clinical rationale for seeking the drug at lower cost, but the legal and safety framework around importation is entirely separate from the pharmacology.

FDA Rules on Personal Importation of Prescription Drugs

The FDA does not have a blanket policy that permits personal importation. The agency's personal importation guidance states that FDA staff "may exercise enforcement discretion" for quantities that represent a 90-day supply or less, provided the drug is for the patient's own use and does not present an unreasonable risk. [6]

That language is permissive, not protective. Customs and Border Protection can still seize a shipment, and the FDA can still reject it even if the supplier is a licensed pharmacy abroad.

What "Enforcement Discretion" Actually Means

"Enforcement discretion" means the FDA chooses not to act, not that the importation is lawful. The Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 331) prohibits importing unapproved or misbranded drugs regardless of quantity. [7] A foreign version of inclisiran, even if manufactured by Novartis in a facility that also supplies U.S. Product, carries a foreign label and is therefore technically "misbranded" under U.S. Law when it crosses the border without FDA clearance.

The practical risk for individual patients is low in enforcement terms, but the legal risk is real. Shipments can be held, destroyed, or returned at no refund from the supplier.

Leqvio-Specific Considerations for Importation

Leqvio is a cold-chain biological product requiring refrigeration at 2°C to 8°C (36°F to 46°F). [8] International mail or courier transit often cannot guarantee an unbroken cold chain for the 24 to 72 hours typical of cross-border shipping. A temperature excursion may render the product ineffective or unsafe, with no visible sign of degradation. The FDA's guidance on biological product storage underlines that temperature-sensitive biologics face additional scrutiny at the border precisely because of this risk. [9]

Patients who receive a dose that has been improperly stored may not achieve the expected 50% LDL-C reduction, and they have no recourse against the foreign pharmacy under U.S. Consumer protection law.

Country-by-Country Price Comparison

Prices below are approximate 2025 public list prices converted to USD. Actual patient cost depends on local insurance, copay structures, and pharmacy negotiated rates. [10]

| Country | Approximate Cost per Dose (USD equivalent) | Regulatory Status | |---|---|---| | United States | $3,500, $4,000 (WAC) | FDA-approved | | United Kingdom | $800, $1,200 (NHS list; patient cost near zero on NHS) | MHRA-approved | | Canada | $1,500, $2,200 (PMPRB-regulated) | Health Canada-approved | | Germany | $1,800, $2,500 (GKV negotiated) | EMA-approved | | Australia | $1,200, $1,600 (PBS-listed) | TGA-approved |

The price differential is substantial, and this is precisely why patients inquire about importation. However, the NHS price is irrelevant to a U.S. Consumer who cannot simply "buy" NHS drugs. Canadian internet pharmacies that sell to U.S. Consumers operate under Health Canada oversight but outside FDA jurisdiction. The legitimacy of any individual supplier must be verified independently. [11]

Legal Alternatives That Are Actually Cheaper in the U.S.

Rather than importing, most patients can access inclisiran at significantly lower net cost through domestic channels. The following framework, developed by the HealthRX clinical team, maps cost-reduction steps by insurance status.

Step 1: Novartis Patient Assistance and Copay Programs

Novartis operates the Leqvio Together program, which includes a copay card for commercially insured patients and a patient assistance program (PAP) for uninsured or underinsured patients who meet income criteria. Eligible commercially insured patients may pay as little as $0 per dose through the copay card. The PAP provides inclisiran at no cost for qualifying patients. [12]

Patients should contact Novartis directly at 1-888-NOW-NOVA or visit the Novartis patient support portal to determine eligibility. Income thresholds and program terms change periodically, so confirming current criteria before assuming eligibility is advisable.

Step 2: Medicare Part B Coverage

Because inclisiran is physician-administered (subcutaneous injection in a clinical setting), it is billed under Medicare Part B as a medical service, not under Part D as a retail pharmacy drug. [13] Part B covers 80% of the Medicare-approved amount after the Part B deductible ($257 in 2025). A Medigap or Medicare Advantage plan may cover the remaining 20%.

The Inflation Reduction Act of 2022 caps out-of-pocket drug costs under Part D at $2,000 annually starting in 2025, but because inclisiran is a Part B drug, that cap does not directly apply. Medicare beneficiaries should confirm their specific plan's Part B cost-sharing before extrapolating.

Step 3: Specialty Pharmacy Negotiated Rates

Leqvio is distributed through specialty pharmacies including CVS Specialty, Walgreens Specialty, and Accredo. These pharmacies often have negotiated rates with PBMs that differ substantially from WAC. Patients without insurance may request cash-pay or self-pay pricing directly from the specialty pharmacy, and some specialty pharmacies have internal assistance programs. [14]

Step 4: 340B Pricing for Qualifying Facilities

Patients who receive care at a 340B-covered entity (certain disproportionate-share hospitals, federally qualified health centers, or Ryan White clinics) may access inclisiran at the 340B ceiling price, which is substantially below WAC. The Health Resources and Services Administration (HRSA) oversees 340B eligibility. [15] Patients can ask their prescribing cardiologist or endocrinologist whether the practice or affiliated hospital qualifies.

Can I Use an HSA or FSA for Leqvio?

Yes. Leqvio is a legally prescribed medication administered in a clinical setting, making it an eligible medical expense under IRS Publication 502, which governs qualified medical expenses for HSA and FSA accounts. [16] Prescription drugs explicitly qualify. The injection itself, billed under CPT 96372 for subcutaneous injection administration, may also be an eligible expense.

Patients should retain the explanation of benefits (EOB) from their insurer and the prescription receipt as documentation for HSA/FSA reimbursement. If the cost is applied to a deductible rather than a copay, the full out-of-pocket amount is reimbursable from the HSA or FSA. [17]

One practical note: FSA funds are use-it-or-lose-it annually (with a grace period of up to 2.5 months or $640 rollover in 2025). Because inclisiran is dosed every six months, a patient receiving two injections per year could plan FSA contributions around those administration dates.

Risks of Unverified Online Pharmacies

The FDA's BeSafeRx campaign and the National Association of Boards of Pharmacy (NABP) have documented that roughly 95% of websites selling prescription drugs online operate outside U.S. Law or applicable international standards. [18] For inclisiran specifically, the risks include:

• Counterfeit product with no active siRNA
• Improper cold-chain storage during transit (see above)
• No physician oversight of administration (inclisiran requires subcutaneous injection, ideally by a trained provider)
• No liability recourse if adverse events occur

The FDA maintains a list of approved online pharmacy sites through its VIPPS (Verified Internet Pharmacy Practice Sites) program via NABP. Patients can verify a U.S.-licensed online pharmacy at nabp.pharmacy before purchasing any prescription medication online. [19]

A 2023 study in JAMA Network Open (N=300 sampled international online pharmacy sites) found that 67% did not require a valid prescription and 43% could not confirm cold-chain compliance for temperature-sensitive biologics. [20]

What Happens if Customs Seizes Your Order?

If U.S. Customs and Border Protection (CBP) intercepts a drug shipment, they refer it to the FDA. The FDA may issue a "refusal of admission" notice under 21 CFR Part 1. [21] The patient typically receives a notice offering the option to re-export the product (back to the sender) or to have it destroyed. There is no guaranteed refund from the foreign pharmacy, and no appeal process that reliably results in the shipment being released.

CBP seized more than 4.8 million parcels containing suspected counterfeit or unapproved drugs in fiscal year 2023 alone, according to CBP annual trade statistics. [22] Inclisiran's cold-chain requirement makes it especially detectable during customs inspection, since temperature indicators may be flagged.

How Physicians and Cardiologists View International Purchasing

The ACC/AHA 2019 guideline on primary prevention of cardiovascular disease notes that patient cost is a legitimate factor in shared decision-making about lipid-lowering therapy. [23] The document specifically states that "cost and access concerns should be addressed" before deprioritizing a guideline-recommended therapy. This framing places the cost-reduction conversation squarely within the physician-patient relationship.

A physician who becomes aware that a patient is importing inclisiran faces no mandatory reporting obligation but does have a duty to counsel the patient on cold-chain risks and to confirm that the administered dose is performing as expected by monitoring LDL-C at each visit. The American College of Cardiology's patient-access position from 2022 recommends that clinicians proactively screen patients for financial barriers before prescribing PCSK9 pathway agents. [24]

"Clinicians should routinely assess the financial burden of lipid-lowering therapies and connect patients with manufacturer assistance programs before writing a prescription that the patient cannot afford to fill," according to the 2023 ACC Expert Consensus Decision Pathway on Novel Therapies for LDL Lowering. [25]

State-Level Importation Programs: A Parallel Path

Several U.S. States have pursued or enacted importation programs under Section 804 of the Federal Food, Drug, and Cosmetic Act, which allows FDA-authorized importation from Canada. [26] As of early 2026, Florida's program has received FDA authorization and is in implementation, while Colorado and New Mexico have submitted Section 804 importation program (SIP) applications.

These state programs target drugs with significant price differentials, and PCSK9 pathway agents are among the drug classes flagged for inclusion. Patients in participating states should monitor their state pharmacy board or health department for updates, as inclisiran's inclusion in a state SIP would create a legal, quality-assured path to lower-cost product.

The FDA's Section 804 framework requires that imported drugs meet the same safety, efficacy, and labeling standards as U.S.-approved products. [27] This is a critical distinction from informal personal importation: SIP drugs are inspected and cleared.

Monitoring Requirements That Affect Total Cost

Inclisiran's cost calculation cannot ignore monitoring. The ACC/AHA recommend checking fasting lipid panel 4 to 12 weeks after initiation and at each dose to confirm response. [28] A non-responder may have PCSK9 pathway resistance or may have received a subpotent dose, including one damaged in transit.

Each lipid panel is a billable lab visit. Patients who import inclisiran without physician involvement may not receive this monitoring, increasing the long-term cardiovascular risk even if the drug cost appears lower.

LDL-C should fall by at least 30% from baseline at the first follow-up after the initial two loading doses. If it does not, the treating physician needs to investigate whether the product was administered correctly, stored correctly, and whether the patient has a variant affecting PCSK9 siRNA efficacy. [29]